Sales of the company's Transcatheter aortic valve replacement (TAVR ... However, the underlying growth rate of 9.8% was lower than the 10.8% increase in the first quarter. While U.S. growth ...

Anteris has been trialling its DurAVR prosthetic aortic valve ... before the raise, after losing 21.4 per cent over the past 12 months. Monday’s $16 a share offer price is lower than $23 at ...